Author

R. El Hajj Chehade

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...

É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al. · The Oncologist · 0 citations

Open access Sep 2026

74 HIF2α Downregulation and Clinical Outcomes in Patients with Clear Cell Renal Cell Carcinoma with and without Sarcomatoid Differentiation

Abstract Background Clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation (sRCC) is associated with poor survival. Recent studies have shown downregulation of hypoxia-related pathways in sRCC (Motzer et al., Cancer Cell, 2020; El Zarif, Semaan et al., Cell Reports, 2024). In this study, we sought to...

R. Nawfal, É. Ibrahim, K. Semaan et al. · The Oncologist · 0 citations